Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
|Videos|September 17, 2014
Insight Sessions Featured at the 2014 NACDS Total Store Expo
The 23 Insight Sessions featured at the 2014 NACDS Total Store Expo addressed a wide range of challenges affecting today's pharmacy landscape.
Advertisement
The 23 Insight Sessions featured at the 2014 National Association of Chain Drug Stores (NACDS) Total Store Expo addressed a wide range of challenges affecting today’s pharmacy landscape, “from
“They’re current, they’re relevant, and they’re what’s going on in the industry,” Whitman notes. “The number is really not important. It’s really the quality of what we want to do and the relevancy of them.”
Advertisement
Related to this article
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
2
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
3
Dostarlimab Receives FDA Accelerated Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
4
Fall 2026 Quiz: Test Your Pharmacy Knowledge!
5